COMET: Correlating Outcomes with Biochemical Markers to Estimate Time-progression in IPF

Trial Location:

Main Campus, Denver, CO

Principal Investigator:

Kevin K. Brown, MD

Trial Sponsor(s):

National Heart Blood and Lung Institute (NHLBI)

Trial Objective:

To determine if there are markers of disease such as proteins or genes (biomarkers) in blood, lung tissue or other body fluids that can be used to predict the course of IPF.

Patient Groups:
135 subjects will be recruited with a goal of following approximately 100 subjects in the longitudinal follow up phase. 

Visits:

• Approximately 9 visits over 80 weeks
• Screening visit to determine eligibility
• Study visits every 16 weeks up to a maximum of 80 weeks

Compensation:

Provided

Who Can Participate:

• Suspected or confirmed diagnosis of IPF
• Age 35-80 years
• Only those with confirmed idiopathic pulmonary fibrosis (IPF) will participate in the longitudinal follow up study.

Enrollment:

Completed and Research Published